[HTML][HTML] Plasminogen activator inhibitor 1 for predicting sepsis severity and mortality outcomes: a systematic review and meta-analysis

TL Tipoe, WKK Wu, L Chung, M Gong, M Dong… - Frontiers in …, 2018 - frontiersin.org
TL Tipoe, WKK Wu, L Chung, M Gong, M Dong, T Liu, L Roever, J Ho, MCS Wong
Frontiers in immunology, 2018frontiersin.org
Objectives Plasminogen activator inhibitor-1 (PAI-1), a crucial regulator of fibrinolysis, is
increased in sepsis, but its values in predicting disease severity or mortality outcomes have
been controversial. Therefore, we conducted a systematic review and meta-analysis of its
predictive values in sepsis. Methods PubMed and Embase were searched until August 18,
2017 for studies that evaluated the relationships between PAI-1 levels and disease severity
or mortality in sepsis. Results A total of 112 and 251 entries were retrieved from the …
Objectives
Plasminogen activator inhibitor-1 (PAI-1), a crucial regulator of fibrinolysis, is increased in sepsis, but its values in predicting disease severity or mortality outcomes have been controversial. Therefore, we conducted a systematic review and meta-analysis of its predictive values in sepsis.
Methods
PubMed and Embase were searched until August 18, 2017 for studies that evaluated the relationships between PAI-1 levels and disease severity or mortality in sepsis.
Results
A total of 112 and 251 entries were retrieved from the databases, of which 18 studies were included in the final meta-analysis. A total of 4,467 patients (36% male, mean age: 62 years, mean follow-up duration: 36 days) were analyzed. PAI-1 levels were significantly higher in non-survivors than survivors [odds ratios (OR): 3.93, 95% confidence interval (CI): 2.31–6.67, P < 0.0001] and in patients with severe sepsis than in those less severe sepsis (OR: 3.26, 95% CI: 1.37–7.75, P = 0.008).
Conclusion
PAI-1 is a significant predictor of disease severity and all-cause mortality in sepsis. Although the predictive values of PAI-1 reached statistical significance, the clinical utility of PAI-1 in predicting outcomes will require carefully designed prospective trials.
Frontiers